Risk-based hepatocellular carcinoma surveillance thresholds using a prediction score in Asian patients with chronic hepatitis B: a nationwide cohort study.

Authors

Won Sohn, Myeongcheol Lee, Danbee Kang, Ju-Yeon Cho, Jung Hee Kim, Soo Jin Park, Yong-Han Paik

Published in

Journal of liver cancer. Sep 03, 2026. Epub Sep 03, 2026.

Abstract

This study aimed to quantify hepatocellular carcinoma (HCC) incidence according to a validated prediction score and to define score-based cut-offs corresponding to surveillance-relevant incidence thresholds in Asian patients with chronic hepatitis B (CHB) receiving antiviral therapy.
We conducted a nationwide population-based cohort study using the Korean National Health Insurance Service database. Adults with CHB initiating nucleos(t)ide analogue therapy between 2012 and 2023 were included, hose with viral coinfections, prior malignancy, or decompensated cirrhosis were excluded. HCC risk was stratified using the HCC-RESCUE score. Incident HCC was the primary outcome. Annual HCC incidence rates and adjusted hazard ratios were estimated using multivariable Cox proportional hazards models.
Among 199,143 treated patients (median follow-up, 7.3 years), 15,233 developed HCC. Adjusted annual HCC incidence increased progressively across risk strata: 0.31% (95% CI 0.24-0.40) in the low-risk group, 1.09% (0.84-1.41) in the intermediate-risk group, and 1.85% (1.44-2.40) in the high-risk group. Compared with the low-risk group, adjusted hazard ratios for HCC were 3.48 (95% CI 3.35-3.61) and 5.90 (5.62-6.19) in the intermediate- and high-risk groups, respectively (all p<0.001). HCC-RESCUE scores corresponding to annual HCC incidence thresholds of 0.2%, 1.5%, and 3.0% were 47, 66, and 90.
In a large antiviral-treated Asian CHB population, prediction score-based stratification revealed a graded spectrum of residual HCC risk and identified incidence-aligned thresholds relevant to surveillance. These findings support incidence-informed refinement of HCC surveillance strategies that complement traditional cirrhosis-based criteria in the antiviral treatment era.

PMID:
42687477
Bibliographic data and abstract were imported from PubMed on 03 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.